PriceTargets.com logo

Longeveron - LGVN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 252.53%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.85 As of 05/1/2026 05:00 PM ET
▲ +0.0006 (0.07%)

This chart shows the closing price for LGVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Longeveron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LGVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LGVN

Analyst Price Target is $3.00
▲ +252.53% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Longeveron in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 252.53% upside from the last price of $0.85.

This chart shows the closing price for LGVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Longeveron. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/15/2025Roth MkmLower TargetBuy ➝ Buy$10.00 ➝ $3.00
3/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
12/6/2024Roth MkmInitiated CoverageBuy$10.00
12/5/2024Roth MkmUpgradeStrong-Buy
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
11/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
9/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/27/2024Maxim GroupLower TargetBuy ➝ Buy$15.00 ➝ $6.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
7/29/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $10.00
5/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
4/29/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $12.00
12/4/2023HC WainwrightReiterated RatingBuy$60.00
3/24/2022Maxim GroupInitiated CoverageBuy$140.00
1/5/2022UBS GroupInitiated CoverageBuy
(Data available from 5/3/2021 forward)

News Sentiment Rating

-0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Longeveron logo
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $0.85
Low: $0.85
High: $0.88

50 Day Range

MA: $0.89
Low: $0.48
High: $1.16

52 Week Range

Now: $0.85
Low: $0.48
High: $1.80

Volume

206,556 shs

Average Volume

702,597 shs

Market Capitalization

$19.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Longeveron?

The following sell-side analysts have issued stock ratings on Longeveron in the last twelve months: Roth Mkm, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for LGVN.

What is the current price target for Longeveron?

0 Wall Street analysts have set twelve-month price targets for Longeveron in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 252.5%. Roth Mkm has the highest price target set, predicting LGVN will reach $3.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $3.00 for Longeveron in the next year.
View the latest price targets for LGVN.

What is the current consensus analyst rating for Longeveron?

Longeveron currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LGVN, but not buy more shares or sell existing shares.
View the latest ratings for LGVN.

What other companies compete with Longeveron?

Other companies that are similar to Longeveron include Athira Pharma, Cypherpunk Technologies, Gossamer Bio, Gain Therapeutics and aTyr Pharma. Learn More about companies similar to Longeveron.

How do I contact Longeveron's investor relations team?

Longeveron's physical mailing address is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. The company's listed phone number is 305-302-7158 and its investor relations email address is [email protected]. The official website for Longeveron is www.longeveron.com. Learn More about contacing Longeveron investor relations.